

Index

- abdominal wall defects, fetal 76
- abortion
 induced, *see* termination of pregnancy
 missed 332
 spontaneous
 estimates 10
 free β -hCG and 134
 low hCG and 332
 previous 8
 see also fetal loss/death
- activins 163, 164
- AFP, *see* α -fetoprotein
- α -fetoprotein (AFP)
 amniotic fluid (AFAFP) 329
 assays, methods 258, 259
 maternal serum (MSAFP) 23, 42, 101–2, 115
 assays 90, 227
 assay imprecision 58, 152–3
 assay modification effects 52–3
 correlation with uE_3 151–2
 elevated, pregnancy outcome 325–9, 333–5
 first trimester 92, 94, 285, 290–1, 313–16
 France 247–8
 information about 23, 276
 low, pregnancy outcome 329–30
 maternal weight correction 63–4, 269
 mechanism of changes 177
 medians used in UK NEQAS 266–9
 MoM distribution 50–1, 52
 neural tube defects 312
 relative risk schedules 9–10
 screening programmes 224, 231–5, 238–43
 smoking and 8
 third trimester 333–5
 risk estimates, UK NEQAS 262–5
 UK NEQAS results 260–1
 UK NEQAS serum pools 256–7

see also free β -human chorionic gonadotrophin/ α -fetoprotein;
 human chorionic gonadotrophin/ α -fetoprotein;
 triple-screening protocols
- age, gestational, *see* gestational age
- age, maternal
 addition of new markers and 40–1
 distribution 295, 296
 free β -hCG/AFP screening and 110
 invasive diagnostic tests and 231
 positive predictive value and 38, 39
 range restriction 44–5
 screening efficiency and 37–8, 65–7, 241–2
 trends in France 247, 248
- age-specific risk, maternal 3–7, 22, 47–8
 determination 32–3
 ethnic/racial differences 6–7, 8
 first trimester trisomies 297
- agglutination tests, hCG 126, 127
- α -human chorionic gonadotrophin (α -hCG) 73–4, 85, 119
 carbohydrate variants 122
 free, *see* free α -human chorionic gonadotrophin
 mRNA, trophoblast cells 126
- amniocentesis 22, 45, 220
 acceptability 24
 awaiting results 279
 decision-making 25–6
 early (EA) 305–6
 emotional support 279
 fetal loss risk 11, 220
 information about 23, 276
 policies 225
 provision for 233, 241, 245–6
 termination of pregnancy after 10–11
- amniotic fluid cells, uncultured
 detection of aneuploidies 212–13, 214–21

Cambridge University Press

978-0-521-45271-7 - Screening for Down's Syndrome

Edited by J. G. Grudzinskas, T. Chard, M. Chapman and H. Cuckle

Index

[More information](#)

340

Index

- amniotic fluid cells, uncultured (*cont.*)
 maternal cell contamination 220
 preparation 212
- anencephaly 90, 251, 280, 281
- anxiety 279
- audit, screening programmes 228–30
- β -core fragment (β -core) 121–2, 126, 127
- β -human chorionic gonadotrophin (β -hCG) 73–4, 85, 119
 assay 102–3, 126–7
 carbohydrate variants 122–3
 degradation products 120–2
 free, *see* free β -human chorionic gonadotrophin
 mRNA, trophoblast cells 126
- biochemical markers, *see* serum markers
- biochemical screening, *see* serum screening
- biparietal diameter (BPD) 59–60, 61
- biparietal diameter:femur length (BPD:FL) ratio 181, 182
- bleeding, vaginal 9
- California 231–5
- cancer antigen 125 (CA 125) 166–7
 amniotic fluid 167
 maternal serum 166, 167
- cardiac malformations 2, 184, 185
- CD34 196
- CD71 (transferrin receptor) 196, 197, 198, 199
- cell sorting, fetal cells 197–8, 201, 206–7
- choriocarcinoma 122–3, 134
- chorionic gonadotrophin, human, *see* human chorionic gonadotrophin
- chorionic villus cells, uncultured
 detection of aneuploidies 212–13, 215–21
 preparation 212
- chorionic villus sampling (CVS) 22–3, 220, 305–6
 awaiting results 279
 provision 233
 termination of pregnancy after 11
- chromosomal abnormalities
 diagnosis
 fetal cells in maternal blood 196–7, 201–6
 serum screening programmes 227–8
 uncultured fetal cells 211–21
- increased nuchal translucency thickness 300, 301
- maternal hCG levels and 78–80
- MSAFP and 329
- nuchal anomalies 297–9
- physiology of biochemical changes 177
- prevalence at 10–13 weeks 295–7
- ultrasound screening 246–7, 253
- see also* fetal abnormalities; trisomy 13; trisomy 18
- chromosome 13-specific probes 212, 220–1
- chromosome 13-specific yeast artificial chromosome 219
- chromosome 18-specific probes
 fetal cells in maternal blood 201, 203–6
 uncultured fetal cells 212, 219, 220–1
- chromosome 21-specific probes
 fetal cells in maternal blood 201, 203–6
 uncultured fetal cells 212, 219, 220–1
- chromosome 21-specific yeast artificial chromosome 219
- coefficients of variation (CV)
 risk estimates 262–3
 serum analytes 58–9, 153–4, 260–1
- complications of pregnancy
 hCG levels and 77
 prediction from mid-trimester biochemistry 325–35
- Schwangerschafts protein 1 and 172
- congenital malformations
 birth of child with 281–2
- Down's syndrome 2
- elevated MSAFP and 329, 333
- see also* chromosomal abnormalities; fetal abnormalities
- cost-benefit analysis
 biochemical screening 27
- California screening programme 234
- cost-effectiveness, serum screening 243
- costs
 Down's syndrome 2–3
 prenatal diagnosis using FISH 221
- cut-off risk values 23–4, 35
- UK NEQAS 272, 273
- cystic hygroma 297, 298
- non-septated (NSCH) 185, 186–7, 189
- septated (SCH) 185, 186, 187, 188
- cytotrophoblast 125, 163
- decision making
 emotional support during 278–80
- facilitating 25–6, 275–8
- decision tree 26
- detection rates 27, 31
 adding new markers and 39, 40, 41, 56–7
- AFP 102
- first-trimester studies 287–90
- free β -hCG 105, 107
 versus hCG 42, 87–9, 105, 107–8
- free β -hCG/AFP 87, 90, 110, 228
- mothers under 35 years old 111–14, 155
- prospective studies 92, 93, 112
- intact hCG 104, 250–1
- intact hCG/AFP 102, 154–5

Cambridge University Press

978-0-521-45271-7 - Screening for Down's Syndrome

Edited by J. G. Grudzinskas, T. Chard, M. Chapman and H. Cuckle

Index

[More information](#)

Index

341

- maternal age and 37–8, 65–7, 241–2
- maternal age range and 44–5
- PAPP-A 320
- sonographic markers 187–8, 190, 303–5
- uE₃ as third marker and 42–4, 154–7
- see also* screening, efficiency
- diagnosis, prenatal, *see* prenatal diagnosis
- diurnal variations, hCG 75
- double-screening protocols 55, 56–9
 - atypical results 68–9
 - error in risk estimation and 153–4
 - screening efficiency and 154–7
 - United Kingdom 224
 - see also* free β -human chorionic gonadotrophin/ α -fetoprotein; human chorionic gonadotrophin/ α -fetoprotein
- drugs, risks 21–2
- duodenal atresia 184
- economics, prenatal diagnosis using FISH 221
- ectopic pregnancy 134
- education, health-care professionals 226, 275–83
- Edward's syndrome, *see* trisomy 18
- efficiency, screening, *see* screening, efficiency
- emotional support 278–82
- epidemiology of Down's syndrome 1–14
- erythroblasts 196
 - see also* red blood cells, nucleated
- estriol, *see* oestriol
- ethnic/racial differences
 - hCG levels 76
 - maternal age-specific risk 6–7, 8
- false-negative results 281–2
- false-positive rates 31
 - adding new markers and 39, 40, 41
 - maternal age and 37–8, 65–7
 - maternal age range and 44–5
 - population standard deviation and 56, 57
 - sonographic markers 303–5
 - uE₃ as third marker and 154–7
 - see also* screening, efficiency
- false positives, *see* serum screening, false positives
- femur length (FL) 181–4
- fetal abnormalities 92
 - sonographic
 - markers of Down's syndrome 181–4
 - screening 246–7, 253
 - transient 185, 187–9
 - termination of pregnancy, *see* termination of pregnancy
 - see also* chromosomal abnormalities; congenital malformations
- fetal cells
 - maternal blood 193–207
 - candidate cells 194–6
 - FISH studies 196–207
 - polymerase chain reaction studies 194
 - uncultured, detection of aneuploidies 211–21
 - materials and methods 212–13
 - results 214–215
- fetal heart monitoring 21
- fetal loss/death 92
 - amniocentesis risk 11, 220
 - Down's syndrome pregnancies 312–13
 - early amniocentesis 306
 - hCG levels and 253, 331
 - MSAFP and 326–8, 330
 - positive serum screening and 333
 - uE₃ and 332
 - see also* abortion, spontaneous
- first trimester 92–7, 285–92, 311–21
 - established markers 313–17
 - factors against screening 312–13
 - fetal nuchal translucency 295–306
 - free β -hCG 92–7, 114–16, 285–92, 313–16
 - inhibin 165
 - PAPP-A 94–5, 97, 285–92, 317–20
 - Schwangerschafts protein 1 175
- FISH, *see* fluorescence *in situ* hybridization
- flow cytometry, fetal cells 197–8, 201, 206–7
- fluorescence *in situ* hybridization (FISH)
 - fetal cells in maternal blood 196–206
 - uncultured fetal cells 211–21
- folic acid supplementation 21
- France 245–53
- free α -human chorionic gonadotrophin (α -hCG) 121
 - Down's syndrome pregnancies 86–7, 314, 317
 - normal pregnancy 120–1, 122, 125
- free β -human chorionic gonadotrophin (free β -hCG) 87–97, 101–16, 121
 - assays 89–90, 102–7, 127, 227, 258–9
 - chromosomal abnormalities and 79, 134
 - clinical applications 133–4
 - correlation with inhibin 164–5
 - first trimester 92–7, 114–16, 285–92, 313–16
 - medians used in UK NEQAS 266–9
 - nicked 121–2, 126, 127, 129, 134
 - normal pregnancy 120, 122, 125
 - second trimester
 - prospective studies 90–2, 93, 110–11
 - retrospective studies 87–90, 108–10
 - younger mothers 111–14

- free β -human chorionic gonadotrophin
(free β -hCG) (*cont.*)
stability on storage 77–8, 89, 129–33
UK NEQAS results 260
UK NEQAS serum pools 256–7
versus intact hCG 42, 87–9, 105, 107–8
- free β -human chorionic gonadotrophin/
 α -fetoprotein (free β -hCG/AFP)
first trimester 95–7
mothers under 35 years 111–14
risk estimates, UK NEQAS 262–5
screening programmes using 224, 227–30
second trimester 90–2, 108–10, 112–14,
115
simultaneous assay 90
versus total hCG/AFP 87–9
see also triple-screening protocols
- free β -human chorionic gonadotrophin:free
 α -human chorionic gonadotrophin
(free β -hCG:free α -hCG) ratio 86
- frequency, Down's syndrome 247
- Gaussian equation, univariate 48–9
- Gaussian frequency distribution
conformation of patient data 9, 50–2
PAPP-A 319
 uE_3 147–8
- Gaussian statistical model 33, 48–9
- gestational age
estimation 226, 240, 243
accuracy 59–63, 70
inter-centre biases 62–3, 70
risk factor calculation and 91–2,
226–7
hCG levels and 75, 249
maternal weight and 315–16
at presentation 312
sonographic markers and 181, 183,
187–9, 190
standardisation for 50–2
glycophorin-A 196, 198, 199
- gonadotrophin-releasing hormone (GnRH)
74–5, 125
- granulocytes, fetal 195
- grief reactions 280
- guilt 280
- haemoglobin (Hb) Lepore–Boston 194
- hCG, *see* human chorionic gonadotrophin
- health-care professionals, training 226,
275–83
- heart monitoring, fetal 21
- height, maternal 65
- HLA antigens, fetal cells 194–5
- human chorionic gonadotrophin (hCG)
73–80
assays 102–5, 126–9, 130–1
factors affecting 77–8
imprecision 58, 152–3
methods 258–9
technical problems 248–9, 250
- biochemistry 73–5
carbohydrate variants 122–3
chromosomal abnormalities and 78–80
control of secretion 74–5, 124–5
correlation with inhibin 164–5
elevated, pregnancy outcome 330–1
factors affecting circulating levels 75–7
first trimester 92–7, 291, 313–16
gestational age and 75, 249
low, pregnancy outcome 332
maternal smoking and 8
maternal weight correction 63–4, 269
mechanism of maternal serum changes
177
medians used in UK NEQAS 266–9
minus β -subunit C-terminal peptide
(β CTP) 120, 121, 127
MoM distribution 50–1
nicked 119, 121, 126, 127
normal pregnancy 119–20, 122, 125
stability on storage 129–33
normal pregnancy 120
screening in France 247–51, 253
severed 119
stored blood 77–8
subunits 73–4, 85–97, 119
see also α -human chorionic
gonadotrophin (α -hCG); β -human
chorionic gonadotrophin (β -hCG)
- trisomy 18 pregnancies 175–7
UK NEQAS results 260–1, 262
UK NEQAS serum pools 256–7
versus free β -hCG 42, 87–9, 105, 107–8
- human chorionic gonadotrophin/
 α -fetoprotein (hCG/AFP)
evaluation 251–2
risk estimates, UK NEQAS 262–5
screening programmes using 224, 238–43
see also triple-screening protocols
- human chorionic gonadotrophin
(hCG)-related molecules 119–35
clinical applications 129–34
detection 126–9
occurrence 119–23
physiology 124–6
hydatidiform mole 133–4
hydronephrosis 184
hydrops fetalis 186, 299
hypertension, pregnancy-induced 328, 331
- immunoassays, hCG 102–5, 126–9, 130–1
impact of Down's syndrome 1–3

Cambridge University Press

978-0-521-45271-7 - Screening for Down's Syndrome

Edited by J. G. Grudzinskas, T. Chard, M. Chapman and H. Cuckle

Index

[More information](#)

- imprecision
 - analytical 57–9, 61, 69
 - error in risk estimates and 152–4
 - UK NEQAS 266
 - ultrasound dating 59–60, 61
- in vitro* fertilisation (IVF) 76
- inbreeding 8
- information
 - presentation to patients 276–7
 - screening programmes 225–6, 232, 243
- inhibin 163–6
 - amniotic fluid 165
 - first-trimester studies 165
 - second-trimester studies 164–5
- interferon-alpha (IFN- α) 75
- intrauterine growth retardation (IUGR)
 - maternal serum hCG and 331
 - MSAFP and 326, 329, 334
 - probability of Down's syndrome and 184
- Klinefelter's (XXY) syndrome 217, 286
- leaflets 226, 277
- likelihood ratio method 33, 36, 47–9, 50
 - atypical results and 67–9
 - observed 35, 37
 - uE₃ as third marker and 42–4
- low birth weight (LBW)
 - elevated MSAFP and 326, 328–9, 334
 - low uE₃ and 332
- lymphocytes, fetal 194–5
- Mahalanobis distance 49, 68–9
- male serum, spiked 256–8
- maternal blood, fetal cells, *see* fetal cells, maternal blood
- mental retardation 1–2
- mid-trimester, *see* second trimester
- midwives, training for serum screening 275–83
- monoclonal antibodies
 - fetal cell sorting 197, 199
 - fetal tissue-specific 195–6
- MSAFP, *see* α -fetoprotein (AFP), maternal serum
- multiples of the median (MoMs) 9, 50–2, 59, 69
 - deficiencies 52–4
 - distributions 50–1, 52
 - maternal weight and 63–4
 - UK NEQAS results 266–9
- National External Quality Assessment Scheme, UK (NEQAS) 255–73
- materials and methods 256–60
- participants 258–9
- questionnaire survey 259–60, 265–72
- results 260–72
 - serum pools 258–60
 - analytical results 260–1, 262
 - risk estimates from 262–5
 - neck, webbed 187, 190
 - neonatal deaths 253, 327
 - Netherlands, screening programme 237–43
 - neural tube defects (NTD) 21, 247, 325
 - screening 90, 226, 237–8, 251, 312
 - normoblasts 197
 - nuchal anomalies 185, 186–7
 - chromosomal defects and 297–301
 - nuchal oedema 181, 183, 185–7, 297–9
 - nuchal translucency (NT) 295–306
 - increased thickness
 - advantages of screening for 303–5
 - chromosomal defects and 297–9, 300, 301
 - prevalence at 10–13 weeks 301–3
 - measurement and reproducibility 301
 - nucleated red blood cells, *see* red blood cells, nucleated
 - obstetricians
 - risk perception 25–6
 - training for serum screening 275–83
 - oestriol 142–4
 - total 142
 - unconjugated, *see* unconjugated oestriol
 - urinary excretion 332
 - oligohydramnios 328
 - omphalocele 241
 - oral contraceptives 9, 21–2
 - oxygen toxicity 21
 - PAPP-A, *see* pregnancy-associated plasma protein A
 - percutaneous umbilical blood sampling (PUBS) 233
 - placental abruption 328, 329, 330, 331
 - policies
 - prenatal diagnosis 10–11
 - screening 27, 41–5, 225
 - polymerase chain reaction (PCR) 194, 196, 198–200
 - population parameters 33–4
 - accuracy of uE₃ data 149–51
 - effect of changing assays 53–4
 - first trimester 313–16
 - importance of correct 54–6, 57, 69
 - screening efficiency and 36–7
 - sources used in UK NEQAS 270–1
 - positive predictive value 38, 39
 - maternal age and 65, 67
 - predictive value, positive, *see* positive predictive value
 - preeclampsia 328, 330, 331

- pregnancy
 complications, *see* complications of pregnancy
 continuation of affected 277–8, 281
 termination, *see* termination of pregnancy
 pregnancy-associated plasma protein A (PAPP-A) 94–5, 97, 285–92, 317–20
 pregnancy-associated plasma protein C (PAPP-C), *see* Schwangerschaftsprotein 1
 pregnancy serum 256
 pregnancy-specific β_1 -glycoprotein, *see* Schwangerschaftsprotein 1
 premature rupture of membranes (PROM) 330, 331, 334
 prenatal diagnosis 22–3
 centres 232
 emotional support 278–80
 fetal cells in maternal blood 201–6
 fetal sex 198–200
 France 245–7
 methods 305–6
 policy issues 10–11
 uncultured fetal cells 211–21
 versus screening 250
 preterm delivery
 elevated MSAFP and 326, 328–9, 334
 maternal serum hCG and 330
 prevalence
 Down's syndrome 247
 fetal trisomies at 10–13 weeks 295–7
 increased nuchal translucency thickness at 10–13 weeks 301–3
 prospective studies 27, 35
 free β -hCG 90–2, 93, 110–11
 triple screening 43, 44
 psychological problems 279–80
 puerperal sepsis 20
 questionnaires, UK NEQAS 259–60, 265–72
 racial differences, *see* ethnic/racial differences
 radiation exposure 9
 red blood cells, nucleated (NRBCs) 196
 FISH studies 201–6
 maternal blood 197–8
 umbilical cord blood 197
 risk
 amniocentesis 11, 220
 chorionic villus sampling 220
 cut-off values, *see* cut-off risk values
 definition 19
 estimation 9–10, 31–45
 analytical error and 152–4
 calculation method 32–3
 gestational age assessment and 91–2, 226–7
 marker frequency distributions and 33–4
 mathematical principle 47–9
 methods, UK NEQAS 266–71
 presentation of results 25, 31
 results, UK NEQAS 262–5
 standardisation for gestational age 50–2
 maternal age-specific, *see* age-specific risk, maternal
 meaning 32
 misperceptions 20–2
 modifiers, correction for 270
 perception 19–27
 Down's syndrome screening 22–7
 history 19–20
 risk factors
 definitive 3
 relative 3–9
 sample collection 226–7
 sandwich-type immunoassays, hCG 127, 128
 SATFA (Support After Termination for Fetal Abnormality) 280
 Schwangerschaftsprotein 1 (SP1) 171–8, 281
 complications of pregnancy 172
 Down's syndrome pregnancies 97, 173–5, 314, 317
 normal pregnancy 172, 173
 trisomy 18 pregnancies 175–7
 screening
 definition 31, 223–4
 efficiency
 addition of new markers and 39–40, 41, 56–7
 determination 34–7
 maternal age and 37–8, 65–7, 241–2
 sonographic 246–7
 uE₃ as third marker and 42–4, 154–7
see also detection rates
 emotional support during 278–9
 false-negative results 281–2
 policies 27, 41–5, 225
 predicting general features 37–41
 programmes
 California 231–5
 France 245–53
 Netherlands 237–43
 United Kingdom 223–30
 risk perception and 22–7
 test combinations, statistics 47–70
 ultrasound 246–7, 253, 303–5

Cambridge University Press

978-0-521-45271-7 - Screening for Down's Syndrome

Edited by J. G. Grudzinskas, T. Chard, M. Chapman and H. Cuckle

Index

[More information](#)

Index

345

- versus diagnosis 250
 - see also* serum screening
- second trimester
 - free β -hCG/AFP 90–2, 108–10, 112–14, 115
 - inhibin 164–5
 - prediction of third-trimester complications 325–35
 - Schwangerschafts protein 1 173–5
- Semmelweis, Ignaz Phillip 20
- serum markers
 - comparison of efficiency 146–7
 - correlations between 41, 315–16
 - distribution parameters, *see* population parameters
 - effect of changing assays 52–4, 55, 69
 - effects of adding new 39–41, 55–6
 - first trimester, *see* first trimester
 - mechanisms of changes 177
 - optimal number 56–9, 153–4
 - see also* specific analytes
- serum pools, UK NEQAS 256–8
- serum screening
 - acceptability 24
 - California 231–5
 - clinician's perspective 25–6
 - false-positives
 - pregnancy outcome 332–3
 - recommended clinical management 335
 - first trimester, *see* first trimester
 - France 247–52
 - mother's perspective 23–4
 - Netherlands 237–43
 - policies 27, 41–5, 225
 - risk estimation, *see* risk, estimation
 - sample collection 226–7
 - test combinations, statistics 47–70
 - third-trimester complications and 325–35
 - training obstetricians and midwives 275–83
 - UK NEQAS 255–73
 - United Kingdom 224, 225–30
 - see also* double-screening protocols; triple-screening protocols
- sex, fetal
 - hCG levels and 76
 - prenatal diagnosis 198–200
- sex chromosome aneuploidies 80, 217, 286
- smoking, maternal 8–9, 76
- SP1, *see* Schwangerschafts protein 1
- spermicides 9
- spina bifida 90, 234, 251, 280
- standard deviation (S.D.), population 55–6, 57
 - accuracy of uE₃ estimates 149–51
 - first-trimester studies 315–16
- statistical model method
 - general features of screening and 37–41
 - screening efficiency estimation 35, 36–7
 - screening policies and 41–5
- statistics, screening by test combination 47–70
- support groups 280
- syncytiotrophoblast 74, 124–5, 163, 171–2
- talipes equinovarus 306
- termination of pregnancy 3
 - decision making 277–8
 - emotional support 279–80
 - Netherlands 237
 - uptake rates 10–11
- third trimester
 - complications, mid-trimester biochemistry and 325–35
 - MSAFP studies 333–5
- thrombospondin receptor 196
- thyroid auto-antibodies 9
- thyroid disease 9
- training, health-care professionals 226, 275–83
- transferrin receptor (CD71) 196, 197, 198, 199
- transvaginal sonography (TCS), 14–16
 - weeks of gestation 184–7
- triple-screening protocols 55–6, 57–9, 141, 235
 - distribution parameters 33–4
 - efficiency 42–4
 - error in risk estimation and 153–4, 265
 - false positives, pregnancy outcome 332–3
 - risk estimates, UK NEQAS 262–5
 - screening efficiency 154–7
 - see also* unconjugated oestriol
- triploidy 79, 241
- trisomy 13 241
 - age-specific risk in first trimester 297
 - first-trimester studies 286, 289
 - hCG levels 79
- trisomy 18 (Edward's syndrome)
 - age-specific risk in first trimester 297
 - atypicality of results 68
 - diagnosis 241
 - fetal cells in maternal blood 197, 201, 205
 - serum screening programmes 227–8
 - uncultured fetal cells 215–19
 - first-trimester studies 94, 286, 288–9, 291
 - hCG levels 79, 175–7, 253
 - MSAFP and 23
 - nuchal anomalies 298
 - SP1 levels 175–7
- trophoblast disease 120–2, 129, 133–4

Cambridge University Press

978-0-521-45271-7 - Screening for Down's Syndrome

Edited by J. G. Grudzinskas, T. Chard, M. Chapman and H. Cuckle

Index

[More information](#)

346

Index

- trophoblasts, maternal blood 195–6
Turner's syndrome 92, 241, 297, 298
- uE₃, *see* unconjugated oestriol
- ultrasound
Down's syndrome 181–91
 markers other than nuchal oedema 181–4
 transient markers 187–9
 gestational dating 59–63, 91–2, 240
 provision 233
 screening 246–7, 253, 303–5
 transvaginal (TVS), at 14–16 weeks 184–7
- umbilical blood
nucleated red blood cells 197
sampling, percutaneous (PUBS) 233
- unconjugated oestriol (uE₃) 102, 141–59
accuracy of population parameters 149–51
assays 143–4, 158
 analytical error 152–4, 158
 effect of modifying 53–4, 55, 143–4, 145
correlation with other markers 151–2
Down's syndrome pregnancies 144–6
first trimester 92, 94, 291, 313–16
low, pregnancy outcome 332
maternal weight correction 269
medians used in UK NEQAS 266–9
- population distributions 147–8
 as second marker 88, 89
 as third marker 42–4, 55–6, 57, 154–7
 UK NEQAS results 260
 UK NEQAS serum pools 256–7
 versus other markers 146–7
- United Kingdom
NEQAS 255–73
screening programmes 223–30
- webbed neck 187, 190
- weight, fetal, hCG levels and 76
- weight, maternal
 correction for 63–5, 91, 269–70
 gestational age and 315–16
 hCG levels and 77
- written information 226, 277
- X-chromosome-specific probes
 fetal cells in maternal blood 201–2
 uncultured fetal cells 212–13, 220–1
- XXY (Klinefelter's) syndrome 217, 286
- XYY syndrome 217
- Y-chromatin 194
- Y-chromosome-specific probes
 fetal cells in maternal blood 195, 196, 198–200, 201–2
 uncultured fetal cells 213, 220–1
- yeast artificial chromosomes 219